Precision Medicine for Rheumatoid Arthritis
News Nov 22, 2016
In a new study, a Yale-led research team identified the mechanism of a gene that raises the risk of severe rheumatoid arthritis in susceptible individuals. The finding may lead to the development of treatment based on the genetic profiles of arthritis patients, the researchers said.
The study was published Nov. 21 in Proceedings of the National Academy of Sciences (PNAS).
Rheumatoid arthritis is a common autoimmune disease that affects an estimated 3 million people and is most prevalent in women. The disease, which destroys cartilage in joints, can lead to severe disability. In its most severe form, vascular inflammation and internal organ damage occur, leading to premature death.
To understand the disease mechanism, Yale professor of medicine Dr. Richard Bucala and his team focused on the disease-causing variants of the gene, MIF, which his lab had found to be associated with severe rheumatoid arthritis.
The research team conducted experiments with cells derived from the rheumatoid joint of patients who either had a disease-causing, high-expression variant of the MIF gene or a disease-protective, low-expression variant of the MIF gene. They found that high-expression MIF variants correlated with increased expression of the MIF receptor protein (CD44) and induced structural changes in the protein that occur in cancerous tissues. These cancerous properties in turn led to the destructive changes in the rheumatoid joint.
“We showed that the presence of the high-expression risk variant led to more MIF production and to structural alterations in a cell surface protein that had long been associated with invasive cancers,” said Bucala. “The high-expression MIF risk gene helps explain the cancer-like properties of the rheumatoid joint.”
This finding could lead to the application of MIF inhibitors, which the laboratory has developed for clinical testing in cancer and in autoimmunity, for severe rheumatoid arthritis in genetically susceptible patients. In the published study, the researchers used these drugs as well as new inhibitors to suppress the invasive effect of MIF on rheumatoid joint cells.
“It’s a precision-medicine approach to treating autoimmune disease,” Bucala noted. “Patients with a risk MIF genotype would be most effectively treated by such drugs.”
Story from Yale University. Original piece written by Ziba Kashef. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Yoo, S.-A., Leng, L., Kim, B.-J., Du, X., Tilstam, P. V., Kim, K. H., … Bucala, R. (2016). MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1612717113
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
NIH Awards BellBrook Labs Phase II Grant to Develop HTS AssaysNews
BellBrook Labs has been awarded a $1 million phase II SBIR grant by the National Institutes of General Medical Sciences to develop assays to detect cGAMP in biological samples.READ MORE
RNA-Modifying Tool Corrects Genetic DiseasesNews
Chemist Matthew D. Disney, PhD has developed a small-molecule-based tool that acts on RNA to selectively delete certain gene products. This deletion tool opens the possibility of creating drugs that can be taken conveniently as pills to correct genetic diseases.READ MORE